RT Journal Article
SR Electronic
T1 OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 569
OP 573
DO 10.3899/jrheum.131246
VO 41
IS 3
A1 Jasvinder A. Singh
A1 William J. Taylor
A1 Nicola Dalbeth
A1 Lee S. Simon
A1 John Sundy
A1 Rebecca Grainger
A1 Rieke Alten
A1 Lyn March
A1 Vibeke Strand
A1 George Wells
A1 Dinesh Khanna
A1 Fiona McQueen
A1 Naomi Schlesinger
A1 Annelies Boonen
A1 Maarten Boers
A1 Kenneth G. Saag
A1 H. Ralph Schumacher
A1 N. Lawrence Edwards
YR 2014
UL http://www.jrheum.org/content/41/3/569.abstract
AB Objective. To determine the extent to which participants at the Outcome Measures in Rheumatology (OMERACT) 11 meeting agree that instruments used in clinical trials to measure OMERACT core outcome domains in acute gout fulfill OMERACT filter requirements of truth, discrimination, and feasibility; and where future research efforts need to be directed. Methods. Results of a systematic literature review and analysis of individual-level data from recent clinical studies of acute gout were presented to OMERACT participants. The information was discussed in breakout groups, and opinion was defined by subsequent voting in a plenary session. Endorsement was defined as at least 70% of participants voting in agreement with the proposition (where the denominator excluded those participants who did not vote or who voted “don’t know”). Results. The following measures were endorsed for use in clinical trials of acute gout: (1) 5-point Likert scale and/or visual analog scale (0 to 100 mm) to measure pain; (2) 4-point Likert scale for joint swelling; (3) 4-point Likert scale for joint tenderness; and (4) 5-point Likert scale for patient global assessment of response to treatment. Measures for the activity limitations domain were not endorsed. Conclusion. Measures of pain, joint swelling, joint tenderness, and patient global assessment in acute gout were endorsed at OMERACT 11. These measures should now be used in clinical trials of acute gout.